瑞银:维持石药集团“买入”评级 降目标价至7港元

新浪港股
02 Apr
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  瑞银发布研报称,石药集团(01093)去年业绩逊预期,主要受到第四季盈利受压,以及研发及销售费用比率提升的影响,展望2025年管理层预期增长将持平。基于最新业绩表现及公司指引,瑞银将石药的目标价从7.2港元下调至7港元,今明两年纯利预测分别下调9.2%及5.5%,维持“买入”评级。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10